Cargando…
Repressing CD147 is a novel therapeutic strategy for malignant melanoma
CD147/basigin, a transmembrane protein, is a member of the immunoglobulin super family. Accumulating evidence has revealed the role of CD147 in the development and progression of various cancers, including malignant melanoma (MM). MM is a malignancy of pigment-producing cells that causes the greates...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421970/ https://www.ncbi.nlm.nih.gov/pubmed/28445958 http://dx.doi.org/10.18632/oncotarget.15709 |
_version_ | 1783234693747965952 |
---|---|
author | Hu, Xing Su, Juan Zhou, Youyou Xie, Xiaoyun Peng, Cong Yuan, Zhimin Chen, Xiang |
author_facet | Hu, Xing Su, Juan Zhou, Youyou Xie, Xiaoyun Peng, Cong Yuan, Zhimin Chen, Xiang |
author_sort | Hu, Xing |
collection | PubMed |
description | CD147/basigin, a transmembrane protein, is a member of the immunoglobulin super family. Accumulating evidence has revealed the role of CD147 in the development and progression of various cancers, including malignant melanoma (MM). MM is a malignancy of pigment-producing cells that causes the greatest number of skin cancer-related deaths worldwide. CD147 is overexpressed in MM and plays an important role in cell viability, apoptosis, proliferation, invasion, and metastasis, probably by mediating vascular endothelial growth factor (VEGF) production, glycolysis, and multi-drug resistance (MDR). As a matrix metalloproteinase (MMP) inducer, CD147 could also promote surrounding fibroblasts to secrete abundant MMPs to further stimulate tumor cell invasion. Targeting CD147 has been shown to suppress MM in vitro and in vivo, highlighting the therapeutic potential of CD147 silencing in MM treatment. In this review article, we discuss CD147 and its biological roles, regulatory mechanisms, and potential application as a molecular target for MM. |
format | Online Article Text |
id | pubmed-5421970 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-54219702017-05-10 Repressing CD147 is a novel therapeutic strategy for malignant melanoma Hu, Xing Su, Juan Zhou, Youyou Xie, Xiaoyun Peng, Cong Yuan, Zhimin Chen, Xiang Oncotarget Review CD147/basigin, a transmembrane protein, is a member of the immunoglobulin super family. Accumulating evidence has revealed the role of CD147 in the development and progression of various cancers, including malignant melanoma (MM). MM is a malignancy of pigment-producing cells that causes the greatest number of skin cancer-related deaths worldwide. CD147 is overexpressed in MM and plays an important role in cell viability, apoptosis, proliferation, invasion, and metastasis, probably by mediating vascular endothelial growth factor (VEGF) production, glycolysis, and multi-drug resistance (MDR). As a matrix metalloproteinase (MMP) inducer, CD147 could also promote surrounding fibroblasts to secrete abundant MMPs to further stimulate tumor cell invasion. Targeting CD147 has been shown to suppress MM in vitro and in vivo, highlighting the therapeutic potential of CD147 silencing in MM treatment. In this review article, we discuss CD147 and its biological roles, regulatory mechanisms, and potential application as a molecular target for MM. Impact Journals LLC 2017-02-25 /pmc/articles/PMC5421970/ /pubmed/28445958 http://dx.doi.org/10.18632/oncotarget.15709 Text en Copyright: © 2017 Hu et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Hu, Xing Su, Juan Zhou, Youyou Xie, Xiaoyun Peng, Cong Yuan, Zhimin Chen, Xiang Repressing CD147 is a novel therapeutic strategy for malignant melanoma |
title | Repressing CD147 is a novel therapeutic strategy for malignant melanoma |
title_full | Repressing CD147 is a novel therapeutic strategy for malignant melanoma |
title_fullStr | Repressing CD147 is a novel therapeutic strategy for malignant melanoma |
title_full_unstemmed | Repressing CD147 is a novel therapeutic strategy for malignant melanoma |
title_short | Repressing CD147 is a novel therapeutic strategy for malignant melanoma |
title_sort | repressing cd147 is a novel therapeutic strategy for malignant melanoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421970/ https://www.ncbi.nlm.nih.gov/pubmed/28445958 http://dx.doi.org/10.18632/oncotarget.15709 |
work_keys_str_mv | AT huxing repressingcd147isanoveltherapeuticstrategyformalignantmelanoma AT sujuan repressingcd147isanoveltherapeuticstrategyformalignantmelanoma AT zhouyouyou repressingcd147isanoveltherapeuticstrategyformalignantmelanoma AT xiexiaoyun repressingcd147isanoveltherapeuticstrategyformalignantmelanoma AT pengcong repressingcd147isanoveltherapeuticstrategyformalignantmelanoma AT yuanzhimin repressingcd147isanoveltherapeuticstrategyformalignantmelanoma AT chenxiang repressingcd147isanoveltherapeuticstrategyformalignantmelanoma |